top of page
Search
In a major article for Drug Discovery World, Dan Williams discussed the opportunities for ASO-based therapies
In a major article for Drug Discovery World, Dan Williams discussed the opportunities for ASO-based therapies
Apr 16
21 views
SynaptixBio’s fourth anniversary celebrated in The Lifesciences Magazine
SynaptixBio’s fourth anniversary celebrated in The Lifesciences Magazine
Apr 16
12 views
Dan Williams discusses gene silencing in this important piece for Drug Target Review
Dan Williams discusses gene silencing in this important piece for Drug Target Review
Apr 16
8 views
In a major article for Pharmaceutical Market Europe, SynaptixBio explains the science behind gene silencing technology
In a major article for Pharmaceutical Market Europe, SynaptixBio explains the science behind gene silencing technology
Jan 30
79 views
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
Dan Williams discusses SynaptixBio’s history, status, and aspirations in a major interview for leading US biotech podcast RAREcast
Jan 9
46 views
The market for ‘gene silencing’ therapies is set to explode
Dan Williams discusses the reasons behind this in FirstWord Pharma. Read his analysis here.
Dec 16, 2024
46 views
Amy Sheridan-Hill, co-founder of the H-ABC Foundation, and Dan Williams in major Mirror story about hopes for new drug
Read the Mirror news story about the H-ABC Foundation and SynaptixBio here.
Oct 31, 2024
69 views
SynaptixBio’s collaboration with leading global drug researcher Evotec featured in European Biotechnology Magazine
See full story of the SynaptixBio and Evotec collaboration here:
Aug 23, 2024
152 views
Dan Williams and Amy Sheridan-Hill, whose son Frankie suffers from H-ABC, interviewed for the Evening Standard.
Read the article here.
Jul 12, 2024
135 views
Dan Williams interviewed for leading podcast, Beyond Biotech
Click here to listen
Jul 12, 2024
28 views
In a major article, Dan Williams considers how to overcome obstacles in rare disease treatment
Rare Diseases, Common Problems by Dan Williams PhD – CEO SynaptixBio
Jun 11, 2024
46 views
Leading biotech appoints senior industry figure as Chief Medical Officer to define clinical strategy and oversee trials
SynaptixBio, the only company developing a treatment for a rare, deadly disease, has appointed Dr Uwe Meya to key position
Jun 11, 2024
129 views
Bioscience Today features major Dan Williams article about collaboration driving rare disease drug development
Bioscience Today has recently published Dan William’s latest article, indeed it’s the lead article on their website and in their magazine to
Apr 30, 2024
55 views
Dan Williams says Big Pharma could help accelerate market introduction for rare disease drugs
SynaptixBio, the only company developing treatment for a rare, deadly disease, says smaller biotech companies could partner with Big Pharma.
Apr 30, 2024
52 views
SynaptixBio awarded second FDA Orphan Drug Designation to boost search for rare disease therapies
SynaptixBio now aiming to develop treatment for second variant of TUBB4A leukodystrophy
Apr 30, 2024
210 views
bottom of page